Abstract 16462: Non Alcoholic Fatty Liver Disease in Coronary Artery Disease Patients - Association With Impaired Glucose Metabolism and With Future Cardiovascular Event Risk
Introduction: Non-alcoholic fatty liver disease (NAFLD) is one of the causes of fatty liver, occurring when fat is deposited in the liver due to causes other than excessive alcohol use. NAFLD is the most common liver disorder in developed countries.
Hypothesis: We hypothesized that the prevalence of NAFLD is high in CAD patients with impaired glucose metabolism and established cardiovascular disease.
Methods: We therefore aimed at investigating its association with the glycemic state as well as its impact on cardiovascular event risk in a large series of 1791 patients with established cardiovascular disease (1472 patients with angiographically proven coronary artery disease and 319 patients with sonographically proven peripheral arterial disease) using the validated fatty liver index to diagnose NAFLD.
Results: At baseline, 42.5%, 36.5%, and 19.8% of our patients had normal fasting glucose (NFG), impaired fasting glucose (IFG), and type 2 diabetes (T2DM), respectively. The prevalence of NAFLD significantly increased from 34.2% over 52.2% to 62.7% through these categories of the glycemic state (p<0.001). Prospectively, we recorded 701 cardiovascular events over a mean follow-up period of 5.6± 3.3 years. Cardiovascular event risk significantly (p<0.001) increased from 30.7% in patients with NFG over 33.3% in patients with IFG to 46.5% in patients with T2DM. NAFLD significantly predicted cardiovascular event risk both univariately and in age- and gender adjusted analyses (HRs 1.23 [1.05-1.45]; p=0.012 and 1.27 [1.08-1.50]; p=0.005, respectively), but not after additional adjustment for the glycemic state (HR 1.15 [0.97 - 1.37]; p=0.098).
Conclusions: We conclude that the prevalence of NAFLD in CAD patients is high and gradually increases with a worsening glycemic state; however, it does not predict cardiovascular events independently from impaired glucose metabolism in this patient population.
Author Disclosures: C.H. Saely: None. D. Zanolin: None. A. Vonbank: None. A. Leiherer: None. P. Rein: None. H. Drexel: None.
- © 2016 by American Heart Association, Inc.